Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Cited by (1,002)

Items 901–1,000 of 1,002

1. Pilot and Safety Trial of Carboplatin, Paclitaxel, and Thalidomide in Advanced Non–Small-Cell Lung Cancer
   Joseph J. Merchant, KyungMann Kim, Minesh P. Mehta, Gregory H. Ripple, Marilyn L. Larson, Diane J. Brophy, L. Hammes, Joan H. Schiller · 2000 · Clinical Lung Cancer
2. Socioeconomic Factors and Survival of Multiple Myeloma Patients
   Kamal Chamoun, Amin Firoozmand, Paolo Fabrizio Caimi, Pingfu Fu, Shufen Cao, Folashade Otegbeye, Leland L. Metheny, Seema V. Patel, Stanton L. Gerson, Kirsten Marie Boughan et al. · 2021 · Cancers
3. ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
   Paola E. Neri, Benjamin G. Barwick, David Jung, Jonathan C. Patton, Ranjan Maity, Inès Tagoug, Caleb K. Stein, Rémi Tilmont, Noémie Leblay, Sungwoo Ahn et al. · 2023 · Blood Cancer Discovery
4. Fact or fiction - identifying the elusive multiple myeloma stem cell
   Joshua N. Kellner, Bei Liu, Yubin Kang, Zihai Li · 2013 · Journal of Hematology & Oncology
5. Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)
   Christopher Paul Venner, Joseph Michael Connors, Heather J. Sutherland, John D. Shepherd, Linda Hamata, Yasser Abou Mourad, Michael J. Barnett, Raewyn C. Broady, Donna L. Forrest, Donna E. Hogge et al. · 2010 · Leukemia & lymphoma/Leukemia and lymphoma
6. Posttransplant maintenance therapy in multiple myeloma: the changing landscape
   Salyka M. Sengsayadeth, Florent Malard, Bipin N. Savani, Laurent Garderet, Mohamad Mohty · 2017 · Blood Cancer Journal
7. Online structure-based screening of purchasable approved drugs and natural compounds: retrospective examples of drug repositioning on cancer targets
   Nathalie Lagarde, Julien Rey, Aram Gyulkhandanyan, Pierre Tufféry, Maria A. Miteva, Bruno O. Villoutreix · 2018 · Oncotarget
8. Repurposing medicinal compounds for blood cancer treatment
   Bronagh McCabe, Fabio Giuseppe Liberante, Ken Mills · 2015 · Annals of Hematology
9. Features and Risk Factors of Peripheral Neuropathy During Treatment with Bortezomib for Advanced Multiple Myeloma
   Jean El Cheikh, Anne‐Marie Stoppa, Réda Bouabdallah, Hugues de Lavallade, Diane Coso, Jean Marc Schiano de Collela, Thérèse Auran-Schleinitz, Jean‐Albert Gastaut, Didier Blaise, Mohamad Mohty · 2008 · Clinical Lymphoma & Myeloma
10. Targeted therapies in multiple myeloma
    Efstathios Kastritis, Andreas Charidimou, Andreas S. Varkaris, Meletios Athanasios Dimopoulos · 2009 · Targeted Oncology
11. Pharmacological Factors Influencing Anticancer Drug Selection in the Elderly
    Veena S. John, Sandeep H. Mashru, Stuart M. Lichtman · 2003 · Drugs & Aging
12. Multiple Myeloma: How Far Have We Come?
    Kenneth Carl Anderson · 2003 · Mayo Clinic Proceedings
13. Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma
    Irene M. Ghobrial, Angela A. Dispenzieri, Kevin L. Bundy, D A Gastineau, S. Vincent Rajkumar, Terry M. Therneau, Martha Q. Lacy, Thomas Elmer Witzig, Mark Robert Litzow, Bryce Raymon Christensen et al. · 2003 · Bone Marrow Transplantation
14. Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience
    Bart Barlogie · 2003 · Seminars in Hematology
15. Complete Resolution of Reflex Sympathetic Dystrophy With Thalidomide Treatment
    S. Vincent Rajkumar, Rafaël Fonseca, Thomas Elmer Witzig · 2001 · Archives of Internal Medicine
16. Thalidomide in refractory and relapsing multiple myeloma
    Joan Bladé · 2001 · Seminars in Oncology
17. New therapies for heart failure: is thalidomide the answer?
    Patrick P. Davey, Houman Ashrafian · 2000 · QJM
18. Novel agents and new therapeutic approaches for treatment of multiple myeloma
    Roberto Ria · 2014 · World Journal of Methodology
19. Role of new treatment approaches in defining treatment goals in multiple myeloma – the ultimate goal is extended survival
    Brian G.M. Durie · 2010 · Cancer Treatment Reviews
20. Drug Repurposing for Epigenetic Targets Guided by Computational Methods
    J. Jesús Naveja, Alfonso Dueñas‐González, José L. Medina‐Franco · 2016 · Elsevier eBooks
21. Blocking MMP-12-modulated epithelial-mesenchymal transition by repurposing penfluridol restrains lung adenocarcinoma metastasis via uPA/uPAR/TGF-β/Akt pathway
    Wen-Yueh Hung, Wei-Jiunn Lee, Guo-Zhou Cheng, Ching-Han Tsai, Yi‐Chieh Yang, Tsung‐Ching Lai, Ji‐Qing Chen, Chi‐Li Chung, Jer‐Hwa Chang, Ming‐Hsien Chien · 2021 · Cellular Oncology
22. Recent advances in the management of multiple myeloma.
    Lalit Kumar, Rakesh Kumar Verma, Venkatraman Srinivasan Radhakrishnan · 2010 · PubMed
23. Safety Profile of Thalidomide after 53 Weeks of Oral Administration in Beagle Dogs
    Steve K. Teo · 2001 · Toxicological Sciences
24. The Chick Embryo Chorioallantoic Membrane in the Study of Angiogenesis and Metastasis
    Doménico Ribatti · 2010 · Springer eBooks
25. The role of new agents in the treatment of non-small cell lung cancer
    Linda E. Bröker, Giuseppe Giaccone · 2002 · European Journal of Cancer
26. Thalidomide‐associated hepatitis: A case report
    Robert Fowler, Kevin Imrie · 2001 · American Journal of Hematology
27. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents
    María Teresa Cibeira, Marı́a Rozman, Marta Segarra, Ester Lozano, Laura Rosiñol, Maria Cinta Cid, Xavier Filella, Joan Bladé · 2008 · Cytokine
28. The Emerging Role of Targeted Therapy for Hematologic Malignancies: Update on Bortezomib and Tipifarnib
    Jean‐Pierre Armand, Alan K. Burnett, Johannes W. Drach, Jean‐Luc Harousseau, Bob Löwenberg, Jesús F. San Miguel · 2007 · The Oncologist
29. The adverse prognostic impact of advanced age in multiple myeloma
    Linda Mileshkin, Henry Miles Prince · 2005 · Leukemia & lymphoma/Leukemia and lymphoma
30. Toxicidad pulmonar por talidomida
    Francisco Carrión Valero, Vicente Bertomeu‐González · 2002 · Archivos de Bronconeumología
31. Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma
    Antonio Pierangelo Palumbo, Faith E. Davies, Martin H. Kropff, Joan Bladé, Michel Delforge, F. Leal da Costa, Ramón García‐Sánz, Stephen Schey, Thierry T.F. Facon, Gareth John Morgan et al. · 2010 · Annals of Hematology
32. An overview of the progress in the treatment of multiple myeloma
    Robert A. Kyle, S. Vincent Rajkumar · 2014 · Expert Review of Hematology
33. The evolution and impact of therapy in multiple myeloma
    Jacob P. Laubach, Paul Gerard Guy Richardson, Kenneth Carl Anderson · 2010 · Medical Oncology
34. Management Strategies for Relapsed/Refractory Multiple Myeloma: Current Clinical Perspectives
    Andrzej J. Jakubowiak · 2012 · Seminars in Hematology
35. Risk factors for multiple myeloma: A hospital-based case–control study in Northwest China
    Qixia Wang, Yiwei Wang, Zhaohua Ji, Xiequn Chen, Yaozhu Pan, Guangxun Gao, Hongtao Gu, Yang Yang, Bernard C. K. Choi, Yongping Yan · 2012 · Cancer Epidemiology
36. Drug Repurposing of Metabolic Agents in Malignant Glioma
    Corinna Seliger, Peter Hau · 2018 · International Journal of Molecular Sciences
37. Incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients
    Somashekar Gopala Krishna, Weizhi Zhao, Monica Grazziutti, Naveen Sanathkumar, Bart Barlogie, Elias J. Anaissie · 2010 · Cancer
38. Changes in Urinary Total Metanephrine Excretion in Recurrent and Malignant Pheochromocytomas and Secreting Paragangliomas
    Laurence Amar, Séverine Peyrard, Patrick Rossignol, Franck Zinzindohoué, Anne‐Paule Gimenez‐Roqueplo, Pierre‐François Plouin · 2006 · Annals of the New York Academy of Sciences
39. Towards a new age in the treatment of multiple myeloma
    Francesco Piazza, Carmela Gurrieri, Livio Trentin, Gianpietro Semenzato · 2007 · Annals of Hematology
40. Management of myeloma-associated renal dysfunction in the era of novel therapies
    Mahmoud Gaballa, Jacob P. Laubach, Robert L Schlossman, Katherine Redman, Kimberly Noonan, Constantine S. Mitsiades, Irene M. Ghobrial, Nikhil C. Munshi, Kenneth Carl Anderson, Paul Gerard Guy Richardson · 2012 · Expert Review of Hematology
41. The Arkansas approach to therapy of patients with multiple myeloma
    Bart Barlogie, Elias J. Anaissie, Frits van Rhee, Mauricio Pineda‐Roman, Maurizio Zangari, John D. Shaughnessy, Joshua Epstein, John J. Crowley · 2007 · Best Practice & Research Clinical Haematology
42. Novel approaches to the treatment of non-small cell lung cancer
    Carlos Gil Ferreira, Cynthia Huisman, Giuseppe Giaccone · 2002 · Critical Reviews in Oncology/Hematology
43. A FRET-Based High Throughput Screening Assay to Identify Inhibitors of Anthrax Protective Antigen Binding to Capillary Morphogenesis Gene 2 Protein
    Michael S. Rogers, Lorna M. Cryan, Kaiane Anoush Habeshian, Lauren F. Bazinet, Thomas P. Caldwell, P. Christine Ackroyd, Ken Christensen · 2012 · PLoS ONE
44. Thalidomide does not modify the prognosis of plasma cell leukemia patients: Experience of a single center
    Maria Teresa Petrucci, Vincenza Martini, Anna Levi, Cristiano Gallucci, Giovanna Palumbo, Patrizia Del Bianco, Concetta Torromeo, Robin Foà · 2007 · Leukemia & lymphoma/Leukemia and lymphoma
45. A thalidomide analogue within vitroantiproliferative, antimitotic, and microtubule-stabilizing activities
    Pui‐Kai Li, Bulbul Pandit, Dan L. Sackett, Zhigen Hu, Jennifer Zink, Jiandong Zhi, Dena Freeman, Robert W. Robey, Karl A. Werbovetz, Andrew Henry Lewis et al. · 2006 · Molecular Cancer Therapeutics
46. Ten Years of Improvement in the Management of Multiple Myeloma: 2000-2010
    Jean‐Luc Harousseau · 2010 · Clinical Lymphoma Myeloma & Leukemia
47. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial
    Niels W.C.J. van de Donk, Bronno van der Holt, Monique C. Minnema, Edo Vellenga, Sandra Croockewit, Marie José Kersten, Peter A. von dem Borne, Paula F. Ypma, Ron Schaafsma, Okke de Weerdt et al. · 2018 · The Lancet Haematology
48. Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide-based regimens in multiple myeloma
    Yonghua Li, Jian Hou, H. Jiang, Dao Wen Wang, Weijun Fu, Zhengang Yuan, Yang Chen, Lili Zhou · 2007 · Haematologica
49. Long‐term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration
    María Teresa Cibeira, Laura Rosiñol, Laia Ramiro, Jordi Esteve, Montserrat Torrebadell, Joan Bladé · 2006 · European Journal Of Haematology
50. Thalidomide in multiple myeloma
    S. Vincent Rajkumar · 2005 · Community Oncology
51. Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells
    Michal Kuczma, Zhi‐Chun Ding, Gang Zhou · 2016 · Critical Reviews in Immunology
52. Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients
    Merav Leiba, Sarah Malkiel, Ivan Budnik, Gabriela Rozic, Abraham Avigdor, Adrian Duek, Arnon Nagler, Gili Kenet, Tami Livnat · 2017 · Blood Cells Molecules and Diseases
53. Trends of incidence, mortality, and survival of multiple myeloma in Switzerland between 1994 and 2013
    Martin Andres, Anita Feller, Volker Arndt · 2018 · Cancer Epidemiology
54. The Development and Pharmacology of Proteasome Inhibitors for the Management and Treatment of Cancer
    Bruce Ruggeri, Sheila J. Miknyoczki, Bruce D. Dorsey, Ai‐Min Hui · 2009 · Advances in pharmacology
55. Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival
    Philipp Schütt, Peter Robert Ebeling, Ulrike Buttkereit, Dieter Brandhorst, Bertram Opalka, Miriam Poser, Siemke Müller, Michael Flaßhove, Thomas Moritz, S. Seeber et al. · 2005 · Annals of Hematology
56. Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma
    Urmeel Patel, Muhammad Ayaz Mir, Jeffrey Michael Sivik, Divisha Raheja, Manoj Kumar Pandey, Giampaolo Talamo · 2015 · Hematology Reports
57. 3-Trifluoromethyl- and 3-difluoromethyl-thalidomides
    Sergej N. Osipov, Pavel Tsouker, Lothar Hennig, Klaus Burger · 2003 · Tetrahedron
58. Nontraditional Cytotoxic Therapies for Relapsed/Refractory Multiple Myeloma
    Mohamad A. Hussein · 2002 · The Oncologist
59. Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR
    Soo Hyun Jin, Tae Il Kim, Kyoung Min Yang, Won Ho Kim · 2006 · European Journal of Pharmacology
60. Modifications to Therapy for Multiple Myeloma: Pegylated Liposomal Doxorubicin in Combination With Vincristine, Reduced-Dose Dexamethasone, and Thalidomide
    Mohamad A. Hussein · 2003 · The Oncologist
61. State of the art therapy in multiple myeloma and future perspectives
    Ulrich Denz, Peter S. Haas, Ralph Wäsch, Hermann Einsele, Monika Martha Engelhardt · 2006 · European Journal of Cancer
62. Thalidomide: An Old Drug with New Action
    Vijay Kumar, Sanjay Chhibber · 2011 · Journal of Chemotherapy
63. Angiogenesis in myeloproliferative neoplasms, new markers and future directions
    Michael Medinger, Jakob Robert Passweg · 2014 · memo - Magazine of European Medical Oncology
64. Tools and methodologies capable of isolating and identifying a target molecule for a bioactive compound
    Satoshi Sakamoto, Mamoru Hatakeyama, Takumi Ito, Hiroshi Handa · 2011 · Bioorganic & Medicinal Chemistry
65. Tumor Angiogenesis Phenotyping by Nanoparticle-facilitated Magnetic Resonance and Near-infrared Fluorescence Molecular Imaging
    Peter A. Jarzyna, Lisette H. Deddens, Benjamin Harris Kann, Sarayu Ramachandran, Claudia Calcagno, Wei Chen, Anita Gianella, Rick M. Dijkhuizen, Arjan W. Griffioen, Zahi Adel Fayad et al. · 2012 · Neoplasia
66. Future agents and treatment directions in multiple myeloma
    Enrique M. Ocio, Constantine S. Mitsiades, Robert Zygmunt Orlowski, Kenneth Carl Anderson · 2013 · Expert Review of Hematology
67. Loss of FBXO9 Enhances Proteasome Activity and Promotes Aggressiveness in Acute Myeloid Leukemia
    R. Willow Hynes-Smith, Samantha A. Swenson, Heather Vahle, Karli J. Wittorf, Mika Caplan, Catalina Amador, R. Katherine Hyde, Shannon M. Buckley · 2019 · Cancers
68. Thalidomide in multiple myeloma – clinical trials and aspects of drug metabolism and toxicity
    Iris Breitkreutz, Kenneth Carl Anderson · 2008 · Expert Opinion on Drug Metabolism & Toxicology
69. Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma
    Athanasios Fassas, Guido J. K. Tricot · 2001 · Seminars in Hematology
70. Topiramate Use Does Not Reduce Flares of Inflammatory Bowel Disease
    Seth D. Crockett, Robin Schectman, Til Stürmer‎, Michael D. Kappelman · 2014 · Digestive Diseases and Sciences
71. Plasma levels of tumour necrosis factor alpha and interleukin‐6 predict progression‐free survival following thalidomide therapy in patients with previously untreated multiple myeloma
    Michael A. Thompson, Thomas Elmer Witzig, Shaji Kunnathu Kumar, Michael Timm, Jessica L. Haug, Rafaël Fonseca, Philip R. Greipp, John Anthony Lust, S. Vincent Rajkumar · 2003 · British Journal of Haematology
72. Genetics and molecular epidemiology of multiple myeloma: The rationale for the IMMEnSE consortium (Review)
    Alessandro Martino · 2011 · International Journal of Oncology
73. A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 ATPase
    Aldo Segura‐Cabrera, Reshmi Tripathi, Xiaoyi Zhang, Lin Gui, Tsui‐Fen Chou, Kakajan Komurov · 2017 · Scientific Reports
74. Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival
    Bart Barlogie, Vanessa Bolejack, Michael J. Schell, John J. Crowley · 2010 · Annals of Hematology
75. Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study
    Sjoerd Hovenga, Simon M. G. J. Daenen, Joost Th. M. de Wolf, Gustaaf Willem Van Imhoff, Hanneke C. Kluin‐Nelemans, Wim J. Sluiter, Edo Vellenga · 2004 · Annals of Hematology
76. Apoptosis in multiple myeloma: Therapeutic implications
    Dharminder Chauhan, Kenneth Carl Anderson · 2001 · APOPTOSIS
77. Thalidomide treatment in multiple myeloma
    Kathrin Strasser, Heinz Ludwig · 2002 · Blood Reviews
78. Pharmacology of Oral Chemotherapy Agents
    Ann Birner · 2003 · Clinical journal of oncology nursing
79. The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine
    Steven Kao, Rozelle M. Harvie, Florian Paturi, Robyn L. Taylor, Ross Davey, Rick Abraham, Stephen John Clarke, Gavin M. Marx, Martin Cullen, Z. Kerestes et al. · 2011 · Lung Cancer
80. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma
    Noopur S Raje, Teru Hideshima, Kenneth Carl Anderson · 2006 · Expert Review of Anticancer Therapy
81. Generating Gene Ontology-Disease Inferences to Explore Mechanisms of Human Disease at the Comparative Toxicogenomics Database
    Allan Peter Davis, Thomas Conrad Wiegers, Benjamin L. King, Jolene Wiegers, Cynthia Grondin, Daniela Sciaky, Robin J. Johnson, Carolyn J. Mattingly · 2016 · PLoS ONE
82. In Silico Drug Design Methods for Drug Repurposing
    Bashir Akhlaq Akhoon, Harshita Tiwari, Amit Nargotra · 2019 · Elsevier eBooks
83. Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing
    Jian Liu, Yehua Zhu, Yufang He, Haohao Zhu, Yi Qin Gao, Zhi Li, Junru Zhu, Xinjie Sun, Fang Fang, Hongmei Wen et al. · 2019 · Journal of Biomolecular Structure and Dynamics
84. Immunomodulatory drugs in the treatment of multiple myeloma
    Yu Abe, Tadao Ishida · 2019 · Japanese Journal of Clinical Oncology
85. CRBN Is a Negative Regulator of Bactericidal Activity and Autophagy Activation Through Inhibiting the Ubiquitination of ECSIT and BECN1
    Mi‐Jeong Kim, Yoon Min, Jae‐Hyuck Shim, Eunyoung Chun, Ki‐Young Lee · 2019 · Frontiers in Immunology
86. Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma
    Ioannis Ntafoulis, Stijn L.W. Koolen, Sieger Leenstra, Martine L.M. Lamfers · 2022 · Cancers
87. Combination therapy with carboplatin and thalidomide suppresses tumor growth and metastasis in 4T1 murine breast cancer model
    Cristina Maria de Souza, Ana Cândida Araújo e Silva, Clarissa de Jesus Ferraciolli, Giovanna Vieira Moreira, Liliane Cunha Campos, Diego Carlos dos Reis, Míriam Teresa Paz Lopes, Mônica Alves Neves Diniz Ferreira, Sílvia Passos Andrade, Geovanni Dantas Cassali · 2013 · Biomedicine & Pharmacotherapy
88. Mechanism of action of immunomodulatory agents in multiple myeloma
    Thomas Reske, Mariateresa Fulciniti, Nikhil C. Munshi · 2010 · Medical Oncology
89. Thalidomide analogues: Tumor necrosis factor-alpha inhibitors and their evaluation as anti-inflammatory agents
    Juan J. Casal, Mariela Bollini, Marı́a Elisa Lombardo, Ana María Bruno · 2015 · European Journal of Pharmaceutical Sciences
90. Cure of myeloma: hype or reality?
    Athanasios Fassas, John D. Shaughnessy, Bart Barlogie · 2004 · Bone Marrow Transplantation
91. Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure
    Ildiko Agoston, Ziad I. Dibbs, Feng Wang, George W. Muller, Jerome B. Zeldis, Douglas L. Mann, Biykem Bozkurt · 2002 · Journal of Cardiac Failure
92. Thalidomide Down-Regulates Transcript Levels of GC-Rich Promoter Genes in Multiple Myeloma
    Liat Drucker, Orit Uziel, Tali Tohami, Hava Shapiro, Judith Radnay, Shai Yarkoni, Meir Lahav, Michael Lishner · 2003 · Molecular Pharmacology
93. Drug Insight: thalidomide as a treatment for multiple myeloma
    Shaji Kunnathu Kumar, Kenneth Carl Anderson · 2005 · Nature Clinical Practice Oncology
94. Response to thalidomide in multiple myeloma: impact of angiogenic factors
    Laura Rosiñol · 2004 · Cytokine
95. Thalidomide and immunomodulatory drugs in the treatment of cancer
    Aristotle Bamias, Meletios Athanasios Dimopoulos · 2005 · Expert Opinion on Investigational Drugs
96. History of Multiple Myeloma
    Robert A. Kyle, David P. Steensma · 2011 · Recent results in cancer research/Recent Results in Cancer Research
97. Thalidomide Dose Proportionality Assessment following Single Doses to Healthy Subjects
    Steve K. Teo, Michael R. Scheffler, Karin A. Kook, William G. Tracewell, Wayne A. Colburn, David Stirling, Steve D. Thomas · 2001 · The Journal of Clinical Pharmacology
98. Myeloma bone disease
    James R. Berenson · 2005 · Best Practice & Research Clinical Haematology
99. Thalidomide–dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide–dexamethasone: a case‐matched study in advanced multiple myeloma
    Massimo Offidani, Sara Bringhen, Laura Corvatta, Patrizia Falco, Monica Marconi, Ilaria Avonto, Maria‐Novella Piersantelli, Claudia Polloni, Mario Boccadoro, Pietro Leoni et al. · 2007 · European Journal Of Haematology
100. PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL.
     Ueno, S, Tatetsu, H, Hata, H, Iino, T, Niiro, H, Akashi, K, Tenen, D G, Mitsuya, H, Okuno, Y · 2009 · Oncogene